As a significant wave of high-value medicines nears the end of patent protection, attention is quickly turning to how companies can bring more affordable generic and biosimilar alternatives to ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

Novo Nordisk has flagged growing generic competition in markets including India as a potential drag on its international business in 2026, highlighting rising pressure on branded obesity and diabetes ...

The chief executive of generic-drug maker Sandoz SDZ-0.73%decrease; red down pointing triangle Group expects the market for unbranded versions of popular weight-loss medicines to be big. Just how big, ...

Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

If your AI-generated marketing content still sounds like everyone else's, the place to start is what happens before the ...

India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Subscribe to read this story ad-free Get unlimited access to ...

Generic semaglutide brands are rapidly expanding India’s obesity and diabetes drug market after slashing prices and challenging Ozempic. Semaglutide generics now outsell Novo Nordisk brands in India.